论文部分内容阅读
前言 1965年Goldstein将小牛胸腺的无菌提取液,纯化命名为胸腺素(Thymosin)。并作了一系列动物实验,证明了它在免疫淋巴细胞分化和成熟中的主导作用。 1968年开始自小牛胸腺提取组分5(Thy-mosin F_5)。经过6年的动物实验和体外活性研究,确认了Thymosin F_5具有免疫调节功能。1974年开始于用临床,通过对癌症、慢性活动性肝炎、系统性红斑狼疮等疾病的疗效观察,证明治疗效果比较显著,而且副作用小。
Preface In 1965 Goldstein named a sterile extract of calf thymus, purified as Thymosin. And made a series of animal experiments to prove its leading role in immune lymphocyte differentiation and maturation. In 1968, we started to extract Thy-mosin F_5 from calf thymus. After six years of animal experiments and in vitro activity studies, confirmed that Thymosin F_5 has immunomodulatory function. Beginning in 1974 with clinical, through the treatment of cancer, chronic active hepatitis, systemic lupus erythematosus and other diseases, the treatment proved that the treatment effect is more significant, and the side effects.